Once-daily Xibrom could be with us soon

Article

Results of a Phase III trial of the once-daily formulation of Xibrom (ISTA Pharmaceuticals) has found it to be both safe and efficacious.

Results of a Phase III trial of the once-daily formulation of Xibrom (ISTA Pharmaceuticals) for the treatment of ocular inflammation and pain associated with cataract surgery, has found it to be both safe and efficacious.

The multicentre study evaluated the once-daily formulation versus placebo in more than 500 patients who had undergone cataract surgery. Preliminary analyses of the results have found the safety profile to be consistent with the currently marketed twice-daily formulation of Xibrom.

ISTA plans to file a supplemental New Drug Application (sNDA) with the FDA during the second half of 2007.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.